Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 21, 2024
Event: Entry into a Material Definitive Agreement (Item 1.01).
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the potential capital raise:
- Maximum Offering Size: Up to $2.4 million in aggregate offering price.
- Compensation to Sales Agent: Up to 3.0% of gross proceeds.
- Intended Use of Proceeds: Research and development (specifically oncology products), working capital, and general corporate purposes.
Material Changes
On May 21, 2024, the Company entered into a Sales Agreement with A.G.P./Alliance Global Partners to establish an "at-the-market" (ATM) equity offering program. This agreement allows the Company to sell shares of common stock at prevailing market prices through the Sales Agent. No shares have been sold under this agreement as of the filing date.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management intends to use net proceeds to fund continued R&D for its drug portfolio, with a specific focus on oncology products. The Company is not obligated to sell any shares under the agreement.
Risks and Contingencies:
- Uncertainty of Execution: There is no assurance that any shares will be sold, nor is there assurance regarding the price, amount, or timing of any potential sales.
- Regulatory Status: The offering is contingent upon the effectiveness of a Registration Statement on Form S-3 filed on May 21, 2024, which was not yet effective at the time of this filing.
- Market Conditions: Sales will be made at prevailing market prices, subject to normal trading practices.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement filed on May 21, 2024.
- Monitor future filings for actual sales volumes and pricing under the ATM program.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination rights and conditions.
- Assess the Company's current cash runway relative to the $2.4 million potential raise to determine the urgency of the offering.